Which one is more effective, talazoparib/tazena or chemotherapy?

In the treatment of breast cancer, especiallyBRCA mutation-related breast cancer, chemotherapy has long dominated the treatment. However, with the advancement of medical treatment, the emergence of targeted drugs such as Talazoparib has brought new options to patients.

From the perspective of pharmacological mechanism, chemotherapy drugs achieve killing effects by interfering with cell division and destroyingDNA synthesis. They have a wide range of effects, but have obvious side effects, especially damage to the bone marrow and gastrointestinal tract, which often limits the course of treatment. Talazoparib is a highly selective PARP inhibitor with a clear target and is particularly suitable for patients with BRCA1/2 mutations. It blocks DNA single-strand damage repair, causing cancer cells to die because they cannot repair DNA, thereby achieving relatively precise treatment.

From an efficacy perspective, studies have shown that talazoparib is more effective than conventional chemotherapy for people with BRCA mutations. It not only shows advantages in delaying disease progression, but also improves the quality of life better than traditional chemotherapy. Patients can often avoid severe hair loss, nausea and vomiting, and severe bone marrow suppression caused by long-term chemotherapy. Especially in terms of tolerance, PARP inhibitors provide new treatment opportunities for some patients who are insensitive to chemotherapy.

However, chemotherapy still plays an irreplaceable role in the classification and treatment stages of many breast cancers. For example, chemotherapy is still a reliable option for patients with undetected BRCA mutations, or when the disease progresses rapidly and does not respond well to targeted drugs. At the same time, talazoparib is not completely free of side effects. Its common risks include anemia, fatigue and platelet decline. If not handled properly, it will also affect the course of treatment.

Therefore, we cannot simply say that talazoparib is definitely more effective than chemotherapy, but we must emphasize "precise population matching." For breast cancer patients with BRCA mutations who are suitable for targeted therapy, talazoparib is generally superior to chemotherapy; in the broader patient population, chemotherapy remains the basic treatment.

Reference materials:https://www.talzenna.com/